Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alks 2680
2. 2648347-56-0
3. N-((21s,24s,52r,53s)-6-oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzena-2(1,4)-cyclohexanacyclooctaphane-53-yl)methanesulfonamide
4. Alixorexton [inn]
5. 3brw4aru66
6. Alks2680
7. Schembl23424870
8. Schembl23425231
9. Alks-2680
10. Gtpl13879
11. Alixorexton (alks 2680)
12. Ex-a12469
13. At48502
14. Compound 2 [wo2021108628a1]
15. Methanesulfonamide, N-[(4s,4ar,7alpha,10alpha)-1,2,3,4,4a,5,7,8,9,10,16,17-dodecahydro-17-oxo-7,10-ethanopyrido[1,2-d][1,7,4]benzodioxaazacyclotridecin-4-yl]-
16. N-[(4s,4ar,7alpha,10alpha)-1,2,3,4,4a,5,7,8,9,10,16,17-dodecahydro-17-oxo-7,10-ethanopyrido[1,2-d][1,7,4]benzodioxaazacyclotridecin-4-yl]methanesulfonamide
17. N-[7,10-cis-(4s,4ar)-17-oxo-1,2,3,4,4a,5,7,8,9,10,16,17-dodecahydro-7,10-ethanopyrido[1,2-d][1,7,4]benzodioxaazacyclotridecin-4-yl]methanesulfonamide
| Molecular Weight | 422.5 g/mol |
|---|---|
| Molecular Formula | C21H30N2O5S |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 93.3 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 671 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
50
PharmaCompass offers a list of Alixorexton API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Alixorexton manufacturer or Alixorexton supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alixorexton manufacturer or Alixorexton supplier.
A Alixorexton manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alixorexton, including repackagers and relabelers. The FDA regulates Alixorexton manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alixorexton API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alixorexton supplier is an individual or a company that provides Alixorexton active pharmaceutical ingredient (API) or Alixorexton finished formulations upon request. The Alixorexton suppliers may include Alixorexton API manufacturers, exporters, distributors and traders.
Alixorexton Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alixorexton GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Alixorexton GMP manufacturer or Alixorexton GMP API supplier for your needs.
A Alixorexton CoA (Certificate of Analysis) is a formal document that attests to Alixorexton's compliance with Alixorexton specifications and serves as a tool for batch-level quality control.
Alixorexton CoA mostly includes findings from lab analyses of a specific batch. For each Alixorexton CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alixorexton may be tested according to a variety of international standards, such as European Pharmacopoeia (Alixorexton EP), Alixorexton JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alixorexton USP).
